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Genetic profiling of poorly 
differentiated sinonasal tumours
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The sinonasal cavities harbour a variety of rare tumour types. Many carry a poor prognosis while 
therapeutic options are limited. Histopathological classification can be difficult, especially for poorly 
differentiated tumours such as olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma 
(SNEC) and sinonasal undifferentiated carcinoma (SNUC). We analysed Affymetrix OncoScan 
genome-wide copy number profiles of these three tumour types, both as originally diagnosed and 
as regrouped by their cytokeratin (Ck) and neuroendocrine (Ne) expression pattern, aiming to find a 
relation between phenotype and genotype. According to the original histopathological classification 
our series consisted of 24 ONB, 11 SNEC and 19 SNUC, while immunohistochemistry indicated 11 
Ck−Ne+/ONB, 18 Ck+Ne+/SNEC, 24 Ck+Ne−/SNUC, and 1 Ck−Ne−/unclassified. As originally 
diagnosed, the three tumour types showed similar copy number profiles. However, when regrouped 
by Ck/Ne immunostaining we found a distinct set of gains and losses; Ck−Ne+/ONB harboured few 
and predominantly whole chromosomes abnormalities, Ck+Ne+/SNEC carried both gains and losses 
in high frequency, and Ck+Ne−/SNUC showed mostly gains. In addition, each tumour carried a 
number of unique chromosomal deletions. Genome-wide copy number profiling supports the value 
of immunohistochemical CkNe staining of ONB, SNEC and SNUC for tumour classification, which is 
important for prognosis and therapeutic decision-making.
The sinonasal cavities are an anatomical area from which emerges a wide histological diversity of neoplasms1. 
Malignant sinonasal tract tumours represent approximately 5% of all head and neck neoplasms and have distinc-
tive etiology, epidemiology, clinical and genetic characteristics2. Sinonasal squamous-cell carcinoma (SNSCC) 
and intestinal-type adenocarcinoma (ITAC) comprise roughly 70% of sinonasal cancers, while the remaining 
30% include a miscellany of neuroendocrine carcinomas, neuroectodermal neoplasms, salivary gland tumours 
and undifferentiated carcinomas3. Diagnosis based primarily on morphological and histological features is a 
challenge for the pathologist, especially for those tumours with poor differentiation such as olfactory neuroblas-
toma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC). 
Moreover, as these tumours have an incidence of approximately 1/100.000 inhabitants, it is hard to acquire suf-
ficient experience. ONB and SNEC can appear very similar and may also be mistaken for SNUC4. Indeed, in the 
past SNUCs were included in the group of high-grade ONB or remained unclassified for absence of specific crite-
ria. The 2017 World Health Organization (WHO) classification of head and neck tumours has defined SNUC as 
a highly aggressive tumour of uncertain histogenesis without evidence of squamous or glandular differentiation1 
thus representing a category with a diagnosis of exclusion. Some evidence for neuroendocrine differentiation in 
SNUC has been reported5,6, but most authors do not classify them as neuroendocrine neoplasms for the lack of 
neuroendocrine immunoreactivity7–9.
Several immunohistochemical markers, including pan-cytokeratin, synaptophysin, chromogranin, 
neuron-specific enolase, CD56, desmin, S-100 and melanin, have been suggested to overcome the classification 
difficulties of poorly differentiated sinonasal tumours4,7,10–14. In addition, some tumours can now be identified by 
molecular genetic analysis15–17, for example NUT (NUclear protein in Testis) carcinoma and SMARCB1 (INI-1) 
1Department Otolaryngology, IUOPA, CIBERONC, Hospital Universitario Central de Asturias, Oviedo, Asturias, 
Spain. 2Department Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain. 3Department of 
Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. 4Department 
Pathology, VUmc, Amsterdam, The Netherlands. José L. Llorente and Mario Hermsen jointly supervised this work. 
Correspondence and requests for materials should be addressed to M.H. (email: mhermsen@hca.es)
Received: 5 October 2017
Accepted: 8 February 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RepoRts |  (2018) 8:3998  | DOI:10.1038/s41598-018-21690-6
deficient sinonasal carcinoma18,19. Until the present moment no specific diagnostic molecular markers are known 
for ONB, SNEC and SNUC.
Correct diagnosis is important because of its relation to clinical outcome20–23. Generally SNEC, SNUC, and 
NUT carcinoma have the worst prognosis with a survival of 9–18 months, in spite of aggressive treatment1,8,23. In 
a study of 23 head and neck neuroendocrine carcinomas including 11 cases occurring in the sinonasal cavities 
(i.e. SNEC), the 5-year overall survival was 91.5% for well and moderately differentiated tumours, dropping to 
21.1% for poorly differentiated cases13. In ONB, 5-year overall survival may go down from 80% to 40% in low 
grade and high grade tumours, respectively1,8,23. All sinonasal tumour patients frequently develop local recur-
rences (50–80%) which are the principal cause of death. Lymph node or distant metastasis are relatively rare, 
occurring in approximately 10–20% of cases1,2,8.
Correct tumour classification is also relevant for therapeutic decision-making. Currently, the optimal treat-
ment for ONB is surgery combined with radiotherapy, while SNUC and SNEC may receive multimodality treat-
ment with chemotherapy4,20,22. With the development of novel inhibitors targeted to specific genetic alterations, 
personalized therapeutic opportunities are becoming available also for sinonasal cancer patients.
In this study we aimed to find a relation between the phenotype and genotype of 54 ONB, SNEC and SNUC, 
using Affymetrix OncoScan genome-wide copy number analysis. We compared the tumours grouped according 
to the original histopathological classification and according to their cytokeratin (Ck) and neuroendocrine (Ne) 
marker expression pattern: ONB was defined as Ck−Ne+, SNEC as Ck+Ne+ and SNUC as Ck+Ne−.
Results
Immunohistochemical classification. Staining of 54 sinonasal tumours with Ck and Ne markers (Fig. 1) 
indicated 11 cases as Ck−Ne+/ONB, all of which orginally diagnosed as ONB. Ck+Ne+/SNEC staining was 
observed in 18 cases, of which 9 had orginally been evaluated as ONB, 8 as SNEC and 1 as SNUC. A Ck+Ne−/
SNUC profile was seen in 24 cases, and of these, 4 had orginally been classified as ONB, 2 as SNEC and 18 
as SNUC. One case orginally classified as SNEC was negative for both markers, Ck−Ne− (Table 1). In total 
17 tumours were differently diagnosed comparing the original and immunohistochemical CkNe classification. 
Immunohistochemical staining for SMARCB1 revealed loss of expression in two Ck+Ne−/SNUC cases and one 
other Ck+Ne−/SNUC case showed focal NUT-1 staining in 30–35% of cells, which was below the threshold of 
positivity.
Genomic profiling. Genome-wide copy number analysis revealed alterations in all 54 tumours. The majority 
had complex karyotypes with gains and losses involving many chromosomes, but a number of cases carried few 
aberrations, mostly being whole chromosome gains or losses (Fig. 1). Overall, the three tumour types originally 
diagnosed showed CNAs involving most chromosomes, but with differences in frequency. Considering the chro-
mosomal regions with >35% CNAs, in ONB we observed gains at 1q, 3q, 7, 8q, 12, 14 and 20, in SNEC gains at 
1q, 3q, 4q, 6p, 8q, 12q and 20q, and losses at 3, 5q, 8p, 9, 10, 13, 16 and 22, and in SNUC gains at 1q, 2q, 3q, 4q, 6p, 
7, 8q, 12, 17q and 20, and losses at 13q and 17p (Fig. 2A–C).
The genomic profiles of the same tumours regrouped according to the Ck and Ne staining demonstrated a 
better defined map of CNA hotspots with higher frequencies within each new group (Fig. 2D–F). The Ck−Ne+/
ONB cases differed considerably from the original ONB and showed a markedly low frequency of CNAs, with 
gains in >35% of cases at 7q, 14q, 18q and 20 and losses at 1p, 2p, 3 and 4 (Table 2). Losses were more frequent 
Figure 1. Representative cases of (A) Ck−Ne+/ONB, (B) Ck+Ne+ and (C) Ck+Ne−/SNUC. Shown are 
H&E staining, cytokeratin, synaptophysin and cromogranin A immunostainings, and genome-wide copy 
number analysis. The Ck−Ne+/ONB case (A) shows few aberrations, mainly involving whole chromosomes. 
The Ck+Ne+/SNEC case (B) carries many aberrations affecting whole chromosomes, chromosome arms 
chromosome segments, and high level amplifications. The Ck+Ne−/SNUC case (C) harbours many aberrations 
affecting whole chromosomes, chromosome arms chromosome segments.
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than gains. Eight of 11 cases carried CNAs concerning whole chromosomes, whereas CNAs of segments of chro-
mosomes were rare (Fig. 1). Ck+Ne+/SNEC tumours showed a profile with frequent gains and losses. Hotspot 
gains of >50% were seen at 1q, 6p, 7, 8q, 12, 14, 17q, 18q and 20, and >35% losses occurred at 5q, 16p and 22q 
(Table 2). Compared to the original SNEC profile, hotspot gains remained similar, whereas losses at 3q, 9, 10 and 
13q became less pronounced. The recurrent aberrations in the Ck+Ne−/SNUC cases did not differ much from 
the original SNUC profile because the immunohistochemical reclassification changed only few cases; many gains 
occurred in >50% of cases, while losses were infrequent, only at 13q and 17p in >35% of cases. One case was 
Ck−Ne-/unclassified and showed mainly whole chromosome CNAs, similar to the Ck−Ne+/ONB tumours.
In contrast to the original classification, the three reclassified tumours showed more pronounced differences 
in their CNA profiles. Ck−Ne+/ONB showed few changes and mostly losses, Ck+Ne+/SNEC had both gains 
and losses in high frequency, and Ck+Ne−/SNUC harboured mostly gains. Especially the Ck−Ne+/ONB group 
stood out by having relatively simple karyotypes with mainly gains or losses of whole chromosomes. The absence 
of CNAs of segments of chromosomes, indicating breakage and chromosomal instability, was in stark contrast 
with the high frequency found in Ck+Ne+/SNEC and Ck+Ne−/SNUC.
A number of chromosomal losses appeared almost exclusively in one of the three tumours: 1p, 2p and 4 in 
Ck−Ne+/ONB, 5q, 6q, 9q, 16p and 22q in Ck+Ne+/SNEC, and 7q and 17p in Ck+Ne−/SNUC. Many gains 
occurred in all three tumours, although gains at 18q were particularly frequent in Ck+Ne+/SNEC, and gains at 
3q, 7p, 11, 16q and 17q especially frequent in Ck+Ne−/SNUC. A notable absence of gains at 8q was observed in 
Ck−Ne+/ONB (Fig. 2). Table 2 lists 22 hotspot regions showing recurrent gains and losses in >35% in at least 
one of the tumour types.
Within the Ck+Ne−/SNUC group, two tumours were found SMARCB1-deficient and one showed NUT-1 
staining in 30–35% of tumour cells. The two SMARCB1 deficient cases had few CNAs, one carried a homozygous 
deletion at 22q11, where the SMARCB1 gene is localized (Fig. 3). The case with focal NUT-1 staining showed 
a complex karyotype with many gains and losses, however, no gains or losses were observed at the NUT-BRD4 
translocation breakpoints on chromosomes 15 and 19 (Fig. 4).
Discussion
Poorly differentiated sinonasal tumours can be hard to diagnose correctly. In this study we collected specimens 
of ONB, SNEC and SNUC from three different hospitals and we regrouped this set of tumours on the basis of 
their Ck and Ne immunoprofile, which changed 17 of 54 tumours to another category. Surprisingly, these cases 
were not only high grade tumours; 5 ONBs with grade II differentiation were reclassified to 2 Ck+Ne+/SNEC 
and 3 Ck+Ne−/SNUC (Table 1). We found that the immunohistochemical CkNe grouping resulted in groups of 
tumours with better defined copy number alteration profiles compared to the original classification.
Ck−Ne+/ONB harboured few abnormalities involving mostly whole chromosome gains and losses. Whole 
chromosome CNAs have been reported previously in ONB24,25. In our study, 8 of 11 Ck−Ne+/ONB were grade 
I and II, therefore it may be that whole chromosome aberrations and a low level of chromosomal instability are 
characteristic for low-grade Ck−Ne+/ONB. Ck+Ne+/SNEC and most Ck+Ne−/SNUC on the other hand, 
revealed many CNAs affecting chromosome segments, chromosome arms and whole chromosomes, thus reflect-
ing a high level of chromosomal instability. Apart from these genome-wide differences, the reclassified tumours 
also harboured distinct gains and losses at specific chromosomal regions, although also common alterations were 
observed, for example gains at chromosomes 7, 14 and 20, and losses at 13q and 16p.
Only few whole genome copy number studies have been published on ONB, SNEC or SNUC to compare 
our data with. The findings of Bockmuhl et al.24 on ONB, with frequent losses at 1p, 3p, 9p, and 10, and gains 
at 20, are similar to our data. Two other ONB studies, however, obtained a different CNA profile25,26. A recent 
next-generation sequencing study on 11 SNUC revealed frequent gains at 1q, 3q, 8q and 17q and losses at 3p and 
17p27. These regions also stood out in our data. We were unable to find genetic studies on SNEC in the literature.
SNUC, even when defined as Ck+Ne−/SNUC, may still be considered a heterogeneous group of malig-
nancies. The 2017 edition of the WHO classification of head and neck tumours recognizes NUT carcinoma 
as a separate entity related to the group of midline carcinomas that generally are highly aggressive, while with 
regard to SMARCB1-deficient carcinoma it remains unclear wether it constitutes a distinct entity1. Additional 
Initial diagnosis IHC classification
Tumour entity Differentiation N° of Cases Ck−Ne+ Ck+Ne+ Ck+Ne− Ck−Ne−
ONB Grade I 3 3
Grade II 10 5 2 3a
Grade III 6 1 5
Grade IV 5 2 2 1
SNEC 11 8 2 1
SNUC 19 1 18b,c
Total 24 11 18 24 1
Table 1. Original diagnosis and IHC classification of 54 sinonasal tumours. Legend. ONB: olfactory 
neuroblastoma; SNEC: sinonasal neuroendocrine carcinoma; SNUC sinonasal undifferentiated carcinoma; Ck: 
pan-cytokeratin marker (AE1/AE3); Ne: neuroendocrine markers (synaptophysin/cromogranin); aone case is 
also SMARCB1-deficient; bone case is also SMARCB1-deficient; cone case shows focal NUT staining.
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immunohistochemical analysis of our Ck+Ne−/SNUC cases yielded one case with partial NUT expression, how-
ever, this was below the threshold of positivity28 and therefore not considered a true NUT carcinoma. Moreover, 
this tumour demonstrated multiple chromosomal segments involved in gains and losses (Fig. 4), while NUT 
carcinomas typically have simple karyotypes often with the t(15;19) translocation as sole aberration18. We have 
no explanation for the NUT expression in this tumour, normally it is restricted to the germ cells of the testis and 
oocytes. Two Ck+Ne−/SNUC cases showed complete absence of SMARCB1 staining and both had simple kary-
otypes, which is in agreement with the literature29. One of the two SMARCB1-deficient cases carried a homozy-
gous deletion on 22q11, where the SMARCB1 gene is localized (Fig. 3), indicating that both copies of the gene had 
been lost. On the basis of these results and the recommendations of the WHO1, we decided to not separate these 
three tumours from our Ck+Ne−/SNUC group.
Correct classification of tumours, either by histological examination, immunohistochemical staining or 
genetic analysis, is important for prognosis and therapeutic decision-making. For a growing number of sinonasal 
tumour types, genetic profiling is the defining tool for classification. Examples are characterizing chromosomal 
translocations t(15;19) NUT-BRD4 in NUT carcinoma, t(11;22) EWSR1-FLI1 in sinonasal Ewing sarcoma/PNET 
and chromosomal rearrangements involving PAX3 Biphenotypic sinonasal sarcoma15–18. Further, HPV-related 
carcinoma with adenoid cystic-like features (also named HPV-related multiphenotypic sinonasal carcinoma) is 
defined by the presence of high-risk HPV in the absence of the t(6;9) MYB-NFIB rearrangement15–17,30. Recently, 
also tumour-specific mutations have been reported, such as EGFR exon 20 mutations in 88% inverted papilloma 
and in 77% of squamous cell carcinoma associated with inverted papilloma, and KRAS mutations in oncocytic 
papillomas31,32. Perhaps the recently described IDH2 mutations may define a subset of SNUC27,33. Apart from the 
analysis on possible cases of SMARCB1-deficient carcinoma and NUT carcinoma, in this study we did not test 
for these additional characterizing genetic abnormalities; although we analysed copy number alterations on a 
genome-wide scale, our method was limited by the fact that characterizing mutations were not evaluated. Clearly 
there is a need for further genetic studies using next-generation sequencing.
As the low incidence of these rare tumours hampers the clinical testing of modern therapies targeted to these 
specific genetic aberrations, multicenter studies and basket trials will be mandatory. Bromodomain inhibitors 
that provoke squamous differentiation and inhibit cell proliferation may be used for patients with NUT carci-
noma, and the first clinical results of appear promising34. Second- and third-generation EGFR inhibitors are being 
developed and tested for lung cancer patients and may be effective also for sinonasal tumour with EGFR exon 20 
mutations31.
In conclusion, copy number alteration profiles of three poorly differentiated and difficult to diagnose sinonasal 
tumours ONB, SNEC and SNUC were more distinctive of each tumour type when classified by immunohisto-
chemical staining with cytokeratin and neuroendocrine markers. As immunohistochemistry is routinely used in 
pathology, our genetic data support the usefulness of this simple staining in the diagnosis of these tumours, which 
in turn may aid prognostication and therapeutic decision-making.
Material and Methods
Patients and tumour material. This study included a total of 54 patients diagnosed as ONB, SNEC and 
SNUC between 1988 and 2011 from Hospital Universitario Central de Asturias (HUCA), Oviedo Spain, from 
VU Medical Center (VUmc), Amsterdam, The Netherlands and from University Medical Center Utrecht (UMC), 
Utrecht, The Netherlands. All experimental protocols were approved by the Institutional Ethics Committee of 
the Hospital Universitario Central de Asturias and by the Regional CEIC from Principado de Asturias (approval 
Figure 2. Copy number aberration profiles of 24 ONB (A), 11 SNEC (B) and 19 SNUC (C) according to the 
original diagnosis, and 11 Ck−Ne+/ONB (D), 18+Ne+/SNEC (E) and 24 Ck+Ne−/SNUC (F) according to 
the immunohistochemical reclassification. The percentage of cases with copy number gains and losses are given 
in blue and red, respectively.
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number: 66/15 for the project PI15/01629). All methods were carried out in accordance with the guidelines of the 
Institutional Ethics Committee of the Hospital Universitario Central de Asturias. Informed consent was obtained 
from all patients. All cases were classified according the criteria of each anatomic pathology service that indicated 
24 cases as ONB, 11 as SNEC and 19 as SNUC. According to the 2017 WHO histological classification1, 13 cases 
ONB cases were low-grade (I–II) and 11 were high-grade (III–IV). SNEC and SNUC cases were not histologically 
further subclassified (Table 1).
Immunohistochemistry. Tissue microarray (TMA) blocks were prepared from formalin fixed, paraffin 
embedded tumour tissues using the Beecher Tissue Microarray (Beecher Instruments, Silver Spring, MD, USA). 
In total 4 TMA blocks were constructed, containing three 1 mm cores from different areas of 54 tumours. Each 
block included normal sinonasal mucosa samples as internal control. Three micrometer sections were stained 
with hematoxylin and eosin and reviewed by one pathologist to determine whether the samples contained a 
good representation of the original tumour blocks. Immunohistochemistry was performed on an automatic 
staining workstation (Dako Autostainer Plus; DakoCytomation, Glostrup, Denmark) with antigen retrieval by 
EnVision FLEX + Mouse (DakoCytomation, Glostrup, Denmark) during 20 minutes. The following antibodies 
were applied: prediluted mouse anti-Cytokeratin clone AE1/AE3, mouse anti-Synaptophysin clone SY38 and 
mouse anti-Chromogranin A clone DAK-A3 (DAKO, Glostrup, Denmark), 1:80 diluted mouse anti-INI-1 clone 
MRQ2 7/ZSI1 (Gennova, Sevilla, Spain), and 1:45 diluted rabbit anti-NUT-1 clone C52B1. The slides were eval-
uated in a double-blind manner by three observers (ALH, BV and MAH). Positivity for Ck was considered when 
>10% tumour cells showed membranous/cytoplasmic staining; Ne was evaluated as positive when either or both 
synaptophysin or chromogranin showed membranous/cytoplasmic staining in >10% tumour cells. ONB was 
defined as Ck−Ne+, SNEC as Ck+Ne+ and SNUC as Ck+Ne−. NUT-1 was scored as positive when >50% of 
tumour cells showed nuclear/cytoplasmic staining. Loss of SMARCB1 staining was defined as complete absence 
of staining on tumour cells while positivity is observed on stromal or inflammatory cells.
Hotspots Alteration
Ck−Ne+/ONB 
(n = 11)
Ck+Ne+/SNEC 
(n = 18)
Ck+Ne−/SNUC 
(n = 24)
1p Loss 27–45% 6–11% 0–8%
2p25.1-14.3 Loss 9–45% 0–6% 0–12%
3 Loss 36% 22–33% 0–25%
4 Loss 36% 6–17% 0–21%
5q Loss 9% 39–56% 4–17%
13q14.3-q21.1 Loss 27% 28–33% 25–38%
16p12.3 Loss 18–27% 28–39% 17–21%
17p13.1-p11.2 Loss 0 17–33% 21–42%
22q12.2-12.3 Loss 9–18% 28–39% 13–21%
1q Gain 0–18% 39–67% 46–66%
2p25-13 Gain 0% 11–39% 25–42%
2q23.3-34 Gain 0% 22–39% 33–50%
3q Gain 0–18% 28–44% 29–71%
4p16 Gain 0 28–39% 29–50%
4p14-13 Gain 0–9% 28–33% 17–46%
4q13-31 Gain 0–18% 28–44% 21–50%
6p Gain 0–9% 33–50% 25–63%
7p Gain 18–27% 22–56% 25–67%
7q11.23-33 Gain 18–36% 22–50% 29–50%
8p Gain 0 33–44% 33–38%
8q Gain 0% 56–83% 45–75%
9p24 Gain 0–9% 39–44% 13–42%
9q22.1-31.1 Gain 0 33–39% 25–42%
11p14.3-p12 Gain 9–18% 11–28% 21–42%
11q13.4-q14.2 Gain 9–18% 11–28% 21–46%
12p Gain 9–27% 44–56% 38–54%
12q Gain 9–27% 44–72% 25–67%
14q Gain 18–55% 28–50% 25–42%
16q23.3-24.3 Gain 9–18% 11–22% 38–50%
17q22-25 Gain 0–18% 28–50% 29–71%
18q Gain 18–36% 44–72% 17–50%
20 Gain 18–55% 28–50% 17–54%
Table 2. Frequencies of chromosomal copy number alterations of sinonasal tumours according to the IHC profile.
www.nature.com/scientificreports/
6SCIENTIfIC RepoRts |  (2018) 8:3998  | DOI:10.1038/s41598-018-21690-6
DNA extraction and genome-wide copy number analysis. The DNA was obtained from 10 slides of 
3 µm of FFPE tissue, after identification of tumour-enriched regions (BV) in a section stained with Haematoxylin 
and Eosin. Special care was taken to obtain high-quality DNA from the formaldehyde-fixed, paraffin-embedded 
tissues. We applied an elaborate extraction protocol35 which includes thorough deparaffinization with xylene, 
Figure 3. SMARCB1-deficient Ck+Ne−/SNUC case. Genome-wide copy number analysis showed a simple 
karyotype, with only a few CNAs, including gain at 3q, focal gains at 1p, 7p and 7q and a loss at 22q (A). 
Immunohistochemical analysis with antibody anti-INI-1 showed absence of SMARCB1 expression, while 
infiltrating lymphocytes were positive (B). Detail of the deletion at 22q: right at the site where the gene 
SMARCB1 is localized (arrow), the deletion is homozygous (C).
Figure 4. Ck+Ne−/SNUC case as suspected NUT carcinoma. Genome-wide copy number analysis showed 
a complex karyotype with losses, gains and amplifications (A). Immunohistochemical analysis with antibody 
anti-NUT-1 showed a focal staining in 30–35% of tumour cells (B). Details of chromosome 15 (C) on 
chromosome 19 (D): at the localizations of the genes NUT-1 and BRD4 (arrows) no aberrations are present.
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methanol washings to remove all traces of the xylene, and incubation in sodium thiocyanate to reduce cross-links. 
Subsequently, the tissue pellet was digested for 3 days in lysis buffer with high doses of proteinase K freshly added 
twice daily. Finally, DNA extraction was done using the ROCHE high pure PCR template preparation kit (Roche 
Diagnosis GmbH, Mannheim, Germany) according to the manufacturer’s recommendations. Quantification of 
DNA was performed using Quant-iT™ PicoGreen®dsDNA Assay Kit (Thermo Fisher Scientific, Madrid, Spain) 
following the manufacturer’s protocol.
Genome-wide copy number analysis was performed using the OncoScan FFPE Assay Kit (Affymetrix, Santa 
Clara, CA, USA) according to the manufacturer’s recommendations. All tumour samples were batch-normalized 
against internal Affymetrix controls. Copy number alterations (CNA) were analysed with Nexus Express for 
OncoScan 3.0.1 (BioDiscovery, Hawthorne CA, USA). At least ten probes per segment were considered as the 
minimum number to define a copy number alteration. Gains were called if the log2 ratio was >0.2 and losses 
<−0.2. High copy number gains were scored when the log2 ratio >1.2 and homozygous deletions <−1.2.
Data availability statement. All data generated in this study will be made available to those interested.
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